Asthma in Day to Day Practice

Similar documents
Biologic Agents in the treatment of Severe Asthma

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Global Initiative for Asthma (GINA) What s new in GINA 2016?

How to distinguish between uncontrolled and severe asthma

Asthma COPD Overlap (ACO)

Getting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital

Difficult Asthma Assessment: A systematic approach

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)

COPD: Current Medical Therapy

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Global Initiative for Asthma (GINA) What s new in GINA 2015?

Asthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital

ASTHMA. Dr Liz Gamble BRI

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Asthma Update I have no professional or personal financial conflicts of interest to disclose.

Asthma Update Jennifer W. McCallister, MD, FACP, FCCP

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness

Significance. Asthma Definition. Focus on Asthma

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

National Asthma Educator Certification Board Detailed Content Outline

Public Dissemination

Update on management of respiratory symptoms. Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Allwin Mercer Dr Andrew Zurek

Current Approaches to Asthma & COPD

Clinical Practice Guideline: Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

Meeting the Challenges of Asthma

Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health.

POCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D.

COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS

Do We Need Biologics in Pediatric Asthma Management?

Diagnosis, Treatment and Management of Asthma

Asthma Pathophysiology and Treatment

Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA

Lecture Notes. Chapter 3: Asthma

Asma e BPCO: le strategie terapeutiche

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence

Prescribing guidelines: Management of COPD in Primary Care

Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University

ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1

CONTENTS. Ageing and Asthma Presentation of Asthma in the Elderly Diagnosis of Asthma in the Elderly... 2

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment

New Therapies for Asthma

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Asthma - An update BTS Asthma Guidelines 2016

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

LINEE GUIDA DELL ASMA: UP TO DATE

Provider Respiratory Inservice

Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products

RESPIRATORY CARE IN GENERAL PRACTICE

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?

Medications Affecting The Respiratory System

A multitude of devices

Asthma Management for the Athlete

THE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital

Treatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology

Nancy Davis, RRT, AE-C

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

Complements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.

What is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective

Known Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.

I have no perceived conflicts of interest or commercial relationships to disclose.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Minimum Competencies for Asthma Care in Schools: School Nurse

In 2002, it was reported that 72 of 1000

PCRS-UK briefing document Asthma guidelines. November 2017

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA

Advance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

11/15/2017. Highgate Private Hospital (Royal Free London NHS Foundation Trust) Causes of chronic cough

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.

Respiratory Pharmacology

Changing Landscapes in COPD New Zealand Respiratory Conference

(Asthma) Diagnosis, monitoring and chronic asthma management

Evaluation and Management of Refractory Asthma

Online supplementary material

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

COPD: A Renewed Focus. Disclosures

Presented by UIC College of Nursing

Chronic Obstructive Pulmonary Disease 1/18/2018

Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More

Chronic Obstructive Pulmonary Disease

COPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?

Transcription:

Asthma in Day to Day Practice VIJAY.K.VANAM

Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical company.

Objectives Diagnosis and Management of Asthma Asthma and COPD Overlap Asthma and Obesity Asthma in Elderly Asthma during Pregnancy.

DIAGNOSIS No GOLD standard test Both Symptoms and airflow limitation should vary in time and intensity. Possible associations with triggers.

How to confirm VARIABILITY BD reversibility test ( >12% and >200 ml) Diurnal PEF variability ( >10%). Exercise Challenge Test ( fall >10% and >200 ml) Bronchial provocation challenge test Variability decreases with treatment or in chronic remodeling.

Phenotypes Asthma is heterogeneous disease Most common Allergic Asthma- well to ICS Non Allergic asthma- less well to ICS Late- Onset Asthma- High doses of ICS Asthma with fixed airflow limitation Asthma and obesity

Other supportive tests Allergy testing- RAST/Skin prick and IgE FeNO levels >50- good short term response to ICS PEF monitoring at and away from work- Occupational or work aggravated Asthma SABA and ICS trial if very nonspecefic.

What next after the Diagnosis Assess Comorbidities Rhinitis, rhinosinusitis, GERD, Obesity, OSA, Depression, anxiety and poor socioeconomic status.

Assess treatment Issues Choice of Drug Delivery system Difference between rescue and maintenance inhaler Inhaler technique and side effects Asthma action plan

Drug delivery mechanism MDI DPI Respimat Nebulizers

MDI Uses propellant ( HFA replaces CFC to protect ozone layer) Advantages of MDIs are as follows: Portability Multidose delivery capability Lower risk of bacterial contamination Disadvantages of MDIs are as follows: Needs correct actuation and inhalation coordination Oropharyngeal drug deposition

DPI Advantages include the following: Breath-actuated Spacer not necessary and portable No need to hold breath for 10 seconds after inhalation No propellant DPI disadvantages include the following: Adequate inspiratory flow required for medication delivery. May result in high pharyngeal deposition Humidity potentially causes powder clumping and reduced dispersal of fine particle mass

Nebulizers Advantages of nebulizers: Provide therapy for patients who cannot use other inhalation modalities (eg, MDI, DPI) Allow administration of large doses of medicine Patient coordination not required No CFC release Disadvantages of nebulizers: Decreased portability Longer set-up and administration time Higher cost May need source of compressed air or oxygen (jet nebulizer)

Management

Add on treatment at Step 4/5/6 Low dose OCS LAMA Anti- IgE Anti- IL 5 BT

Anti IgE Indicated for >6 years of age with moderate to severe persistent asthma with positive skin test or invitro reactivity to perennial aeroallergen and whose symptoms are inadequately controlled with ICS. A total serum IgE level between 30 and 700 (1500 in Europe) international units/ml. Reduces exacerbations. Anti-IgE as novel therapy for the treatment of asthma.aufick RB Jr SOCurr Opin Pulm Med. 1999;5(1):76.

Anti IL-5- Eosinophilic phenotype Available as Sub cut or IV infusion. While the FDA did not set a specific threshold, NICE recommends a threshold of an absolute blood eosinophil 300/microL for one drug and >400/microL for other drug. However, this threshold is less clear in patients on daily systemic glucocorticoids.

SLIT SLIT in adults with HDM sensitive patients with allergic rhinitis who have exacerbations despite ICS, provided FEV1>70% predicted has shown promising results.

Bronchial Thermoplasty Bronchial thermoplasty (BT) refers to a technique of applying heat (via a device that delivers localized controlled radiofrequency waves) to the airways during bronchoscopy, which reduces the increased mass of airway smooth muscle associated with asthma

Procedure typically entails three separate bronchoscopies under moderate sedation about three weeks apart. (AIR2) trial (RISA) trial However, all of the trials excluded subjects with more than three exacerbations per year or an FEV 1 <50 percent of predicted, so the safety and efficacy of BT for these patients is not known.

Step Up or Step Down

Non Pharmacological interventions Cessation of smoking and environmental toxins. Avoidance of occupational sensitizers. Aspirin and NSAIDs Aspirin exacerbated respiratory disease. Weight reduction and vaccinations.

Beta Blockers Beta blockers appear to be safe in patients with COPD and indeed may reduce mortality and exacerbations. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.aurutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW PMID20498416

The acute clinical effects of beta-1-selective beta blockers and nonselective beta blockers on pulmonary function in patients with asthma were examined in a systematic review and metaanalysis of 32 randomized trials including 1367 patients. Meta-analysis suggests that even beta-1-selective antihypertensive agents should be used with caution in patients with asthma, especially in those with severe obstruction or markedly reduced pulmonary function at baseline.

As for asthma, chronic use of cardioselective beta blockers doesn't seem to precipitate asthma attacks in mild or moderate asthma. Beta blockers are key component of care for people who have had previous heart attacks or who have systolic heart failure.. It seems unlikely that the risks of worsening asthma or COPD outweigh the potential benefits of beta blocker use, in these patients.

Asthma and COPD overlap Its not a single disease entity. Consider in patients who are smokers and elderly. Avoid high dose ICS and combine with LABA. Prefer not to use ICS alone or LABA alone.

Asthma and Obesity

Considered one of the major risk factors for development of Asthma. Tends to be more severe. 3 main reasons for above effects- Mechanical factors, inflammatory mediators and immune responses.

Obesity and Lung function ERV and so FRC decreases. Tidal breaths at low FRC causes increased airway resistance.

Obesity Inflammation &Immune Response State of chronic, low grade inflammation. Obesity increases adipose tissue resident macrophages. Macrophages increases Il-6, TNF alpha and Plasminogen activator inhibitor. Increased leptins (proinflammatory) and decreased Adiponectins (antiinflammatory).

Obese patients with asthma are relatively resistant to ICS but respond in a similar manner to anti leukotrienes as do lean asthmatics.

Asthma in Elderly

2 Categories Asthma in Elderly Persistence or recurrence of childhood Asthma. New symptoms of Asthma as elderly. Differentiate Asthma with COPD and Heart failure. Under diagnosed because of pts paradox of well being and lower health expectations.

Structural changes of aging lung Thickened airway wall and loss of eleastic recoil. Kyphosis and chest wall compliance Sarcopenia.

Overlap with COPD No DPI- needs high flow velocity Using spacer device Using nebulizers in NH patients.

Asthma and pregnancy

1/3 rd rule. Most of the medications are Category C but advantages of actively treating asthma markedly outweigh any potentionial risks. Don t step down the therapy. Monitor for neonatal hypoglycemia if SABA is used in high doses 48 hrs before delivery. If prednisone >7.5 mg for >2 weeks, give hydrocortisone during delivery.